Abstract
In a multistate network that enrolled adults hospitalized during March-July 2021, effectiveness of 2 doses of mRNA vaccine against COVID-19-associated hospitalization was sustained over a follow-up period of 24 weeks (approximately 6 months). These findings of sustained VE were consistent among subgroups at highest risk for severe outcomes from COVID-19, including older adults, adults with three or more chronic medical conditions, and those with immunocompromising conditions. Overall VE in adults with immunocompromising conditions was lower than that in those without immunocompromising conditions but was sustained over time in both populations.
Original language | English (US) |
---|---|
Pages (from-to) | 1156-1162 |
Number of pages | 7 |
Journal | Morbidity and Mortality Weekly Report |
Volume | 70 |
Issue number | 34 |
DOIs | |
State | Published - Aug 2021 |
Externally published | Yes |
ASJC Scopus subject areas
- Epidemiology
- Health(social science)
- Health, Toxicology and Mutagenesis
- Health Information Management
Fingerprint
Dive into the research topics of 'Sustained effectiveness of pfizer-biontech and moderna vaccines against covid-19 associated hospitalizations among adults - united states, march-july 2021'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Sustained effectiveness of pfizer-biontech and moderna vaccines against covid-19 associated hospitalizations among adults - united states, march-july 2021. / Tenforde, Mark W.; Self, Wesley H.; Naioti, Eric A.; Ginde, Adit A.; Douin, David J.; Olson, Samantha M.; Talbot, H. Keipp; Casey, Jonathan D.; Mohr, Nicholas M.; Zepeski, Anne; Gaglani, Manjusha; McNeal, Tresa; Ghamande, Shekhar; Shapiro, Nathan I.; Gibbs, Kevin W.; Files, D. Clark; Hager, David N.; Shehu, Arber; Prekker, Matthew E.; Erickson, Heidi L.; Gong, Michelle N.; Mohamed, Amira; Henning, Daniel J.; Steingrub, Jay S.; Peltan, Ithan D.; Brown, Samuel M.; Martin, Emily T.; Monto, Arnold S.; Khan, Akram; Hough, Catherine L.; Busse, Laurence W.; ten Lohuis, Caitlin C.; Duggal, Abhijit; Wilson, Jennifer G.; Gordon, Alexandra June; Qadir, Nida; Chang, Steven Y.; Mallow, Christopher; Rivas, Carolina; Babcock, Hilary M.; Kwon, Jennie H.; Exline, Matthew C.; Halasa, Natasha; Chappell, James D.; Lauring, Adam S.; Grijalva, Carlos G.; Rice, Todd W.; Jones, Ian D.; Stubblefield, William B.; Baughman, Adrienne; Womack, Kelsey N.; Lindsell, Christopher J.; Hart, Kimberly W.; Zhu, Yuwei; Stephenson, Meagan; Schrag, Stephanie J.; Kobayashi, Miwako; Verani, Jennifer R.; Patel, Manish M.
In: Morbidity and Mortality Weekly Report, Vol. 70, No. 34, 08.2021, p. 1156-1162.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Sustained effectiveness of pfizer-biontech and moderna vaccines against covid-19 associated hospitalizations among adults - united states, march-july 2021
AU - Tenforde, Mark W.
AU - Self, Wesley H.
AU - Naioti, Eric A.
AU - Ginde, Adit A.
AU - Douin, David J.
AU - Olson, Samantha M.
AU - Talbot, H. Keipp
AU - Casey, Jonathan D.
AU - Mohr, Nicholas M.
AU - Zepeski, Anne
AU - Gaglani, Manjusha
AU - McNeal, Tresa
AU - Ghamande, Shekhar
AU - Shapiro, Nathan I.
AU - Gibbs, Kevin W.
AU - Files, D. Clark
AU - Hager, David N.
AU - Shehu, Arber
AU - Prekker, Matthew E.
AU - Erickson, Heidi L.
AU - Gong, Michelle N.
AU - Mohamed, Amira
AU - Henning, Daniel J.
AU - Steingrub, Jay S.
AU - Peltan, Ithan D.
AU - Brown, Samuel M.
AU - Martin, Emily T.
AU - Monto, Arnold S.
AU - Khan, Akram
AU - Hough, Catherine L.
AU - Busse, Laurence W.
AU - ten Lohuis, Caitlin C.
AU - Duggal, Abhijit
AU - Wilson, Jennifer G.
AU - Gordon, Alexandra June
AU - Qadir, Nida
AU - Chang, Steven Y.
AU - Mallow, Christopher
AU - Rivas, Carolina
AU - Babcock, Hilary M.
AU - Kwon, Jennie H.
AU - Exline, Matthew C.
AU - Halasa, Natasha
AU - Chappell, James D.
AU - Lauring, Adam S.
AU - Grijalva, Carlos G.
AU - Rice, Todd W.
AU - Jones, Ian D.
AU - Stubblefield, William B.
AU - Baughman, Adrienne
AU - Womack, Kelsey N.
AU - Lindsell, Christopher J.
AU - Hart, Kimberly W.
AU - Zhu, Yuwei
AU - Stephenson, Meagan
AU - Schrag, Stephanie J.
AU - Kobayashi, Miwako
AU - Verani, Jennifer R.
AU - Patel, Manish M.
N1 - Funding Information: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Samuel M. Brown reports personal fees from Hamilton, institutional fees from Faron Pharmaceuticals and Sedana, grants from Janssen, the National Institutes of Health (NIH), and the Department of Defense (DoD), book royalties from Oxford University and Brigham Young University, outside the submitted work. Jonathan D. Casey reports grants from NIH, outside the submitted work. Steven Y. Chang was a speaker for La Jolla Pharmaceuticals in 2018 and consulted for PureTech Health in 2020. James D. Chappell reports grants from NIH during the conduct of the study. Matthew C. Exline reports support from Abbott Labs for sponsored talks, outside the submitted work. D. Clark Files reports personal consultant fees from Cytovale and is a data and safety monitoring board (DSMB) member from Medpace, outside the submitted work. Adit A. Ginde reports grants from NIH, DoD, AbbVie, and Faron Pharmaceuticals, outside the submitted work. Michelle N. Gong reports grants from NIH and the Agency for Healthcare Research and Quality (AHRQ), DSMB membership fees from Regeneron, and personal fees from Philips Healthcare, outside the submitted work. Carlos G. Grijalva reports consultancy fees from Pfizer, Merck, and Sanofi-Pasteur; grants from Campbell Alliance/Syneos Health, NIH, the Food and Drug Administration, AHQR, and Sanofi, outside the submitted work. David N. Hager reports salary support from Incyte Corporation, the Marcus Foundation, and EMPACT Precision Medicine via Vanderbilt University Medical Center, outside the submitted work. Natasha Halasa reports grants and nonfinancial support from Sanofi, and Quidel outside the submitted work. Daniel J. Henning reports personal consultant fees from Cytovale and Opticyte. Akram Khan reports grants from United Therapeutics, Johnson & Johnson, 4D Medical, Lung LLC, and Reata Pharmaceuticals, outside the submitted work. Adam S. Lauring reports personal fees from Sanofi and Roche, outside the submitted work. Christopher J. Lindsell reports grants from NIH, DoD, and the Marcus Foundation; contract fees from bioMerieux, Endpoint LLC, and Entegrion Inc, outside the submitted work and has a patent for risk stratification in sepsis and septic shock issued. Emily T. Martin reports personal fees from Pfizer and grants from Merck, outside the submitted work. Arnold S. Monto reports consulting fees from Sanofi-Pasteur and Seqirus outside the submitted work. Ithan D. Peltan reports grants from NIH and Janssen Pharmaceuticals and institutional support from Asahi Kasei Pharma and Regeneron, outside the submitted work. Todd W. Rice reports personal fees from Cumberland Pharmaceuticals, Inc. and personal fees from Avisa Pharma, LLC and Sanofi, outside the submitted work. Wesley H. Self reports consulting fees from Aeprio Pharmaceuticals and Merck outside the submitted work. No other potential conflicts of interest were disclosed. Publisher Copyright: © 2021 Department of Health and Human Services. All rights reserved.
PY - 2021/8
Y1 - 2021/8
N2 - In a multistate network that enrolled adults hospitalized during March-July 2021, effectiveness of 2 doses of mRNA vaccine against COVID-19-associated hospitalization was sustained over a follow-up period of 24 weeks (approximately 6 months). These findings of sustained VE were consistent among subgroups at highest risk for severe outcomes from COVID-19, including older adults, adults with three or more chronic medical conditions, and those with immunocompromising conditions. Overall VE in adults with immunocompromising conditions was lower than that in those without immunocompromising conditions but was sustained over time in both populations.
AB - In a multistate network that enrolled adults hospitalized during March-July 2021, effectiveness of 2 doses of mRNA vaccine against COVID-19-associated hospitalization was sustained over a follow-up period of 24 weeks (approximately 6 months). These findings of sustained VE were consistent among subgroups at highest risk for severe outcomes from COVID-19, including older adults, adults with three or more chronic medical conditions, and those with immunocompromising conditions. Overall VE in adults with immunocompromising conditions was lower than that in those without immunocompromising conditions but was sustained over time in both populations.
UR - http://www.scopus.com/inward/record.url?scp=85114093646&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114093646&partnerID=8YFLogxK
U2 - 10.15585/MMWR.MM7034E2
DO - 10.15585/MMWR.MM7034E2
M3 - Review article
C2 - 34437524
AN - SCOPUS:85114093646
VL - 70
SP - 1156
EP - 1162
JO - Morbidity and Mortality Weekly Report
JF - Morbidity and Mortality Weekly Report
SN - 0149-2195
IS - 34
ER -